Abstract:INTRODUCTION AND OBJECTIVES: Sphingosine kinase 1 (SphK1) is the major source of the bioactive lipid and GPCR (G-proteincoupled receptor) agonist sphingosine 1-phosphate (S1P). Numerous studies have documented that SphK1-S1P signalling has multiple functions in tumorigenesis. The present study was conducted to investigate the expression of SphK1-S1P signalling and its prognostic significance in renal cell carcinoma (RCC). Meanwhile, we set out to SphK1 as a novel molecular target in RCC and examine its role in tumor cell growth and sunitinib resistance in vitro and in vivo. METHODS: In this study, SphK1 expression levels as well as clinicopathological significance were evaluated in RCC cell lines and primary RCC clinical specimens by immunohistochemistry, immunofluorescence assay, qRT-PCR and western blot. We assessed the levels of S1P and Sph in tumor tissues by HPLC analysis and in the plasma of RCC patients and healthy controls by LC-MS/MS analysis. In vitro and in vivo knockdown or overexpression of SphK1 in RCC cell lines was used to determine its effecton tumor growth, cellular proliferation, colony formation, migration, invasion, and apoptosis. We conducted a phosphoprotein antibody array to identify ectopic phosphorylated proteins induced in 786-O cells with/without SphK1 expression vector. In addition,we further evaluated the effect of SphK1 antagonist fingolimod (FTY720) in RCC in vitro and in vivo, as a single agent or in combination with sunitinib, and attempted to explore its anticarcinogenic mechanisms. RESULTS: We identify upregulation of SphK1 significantly associated with poor prognosis of RCC patients, which contributing to renal proliferation, colony formation, migration and survival. Suppression of SphK1 activity either by shRNA or pharmacologic inhibitior FTY720 suppresses cell growth in vitro and in vivo. A comprehensive phosphoprotein antibody array reveals that SphK1 overexpression promoted RCC progression by regulating the Akt/mTOR pathway. SphK1 could act as a canonical regulator of hypoxia-inducible HIF-1&agr; and HIF-2&agr; in RCC cells. Moreover, stem-like phenotype due to sunitinib administration via oncogenic activation of SphK1 could be ameliorated by SphK1 shRNA and FTY720. FTY720 administration enhanced tumor growth inhibition effect of sunitinib treatment on RCC cells in vitro and in vivo. CONCLUSIONS: Our results unraveled that increased SphK1 kinase activation defines an important mechanism for maintaining stemlike phenotype and sunitinib resistance, therefore contributes to tumour development and represents therapeutic targets for RCC. Source of Funding: none

Inactivation of endothelial cell phosphoinositide 3-kinase β inhibits tumor angiogenesis and tumor growth

Sunitinib Induced Resistance of Endothelial Cells by Up-Regulating P-glycoprotein and PI3K/Akt Pathway

Receptor tyrosine kinase inhibitor Sunitinib and integrin antagonist peptide HM-3 show similar lipid raft dependent biphasic regulation of tumor angiogenesis and metastasis.

Sunitinib Acts Primarily on Tumor Endothelium Rather Than Tumor Cells to Inhibit the Growth of Renal Cell Carcinoma.

Effects of Vascular-Endothelial Protein Tyrosine Phosphatase Inhibition on Breast Cancer Vasculature and Metastatic Progression

Multimodal microvascular imaging reveals that selective inhibition of class I PI3K is sufficient to induce an antivascular response.

RETRACTED ARTICLE: Receptor tyrosine kinase inhibitor Sunitinib and integrin antagonist peptide HM-3 show similar lipid raft dependent biphasic regulation of tumor angiogenesis and metastasis

The Mechanism Of Action And Resistance Of Sunitinib In Rcc.

Sunitinib Facilitates Metastatic Breast Cancer Spreading by Inducing Endothelial Cell Senescence

Enhanced antitumor efficacy by blocking activation of the phosphatidylinositol 3-kinase/Akt pathway during anti-angiogenesis therapy

Phosphoinositide 3-Kinase As a Therapeutic Target in Angiogenic Disease.

SUMOylated NICD in Endothelial Cell Suppresses Tumor Angiogenesis

Abstract 1644: Sunitinib Primarily Acts on Tumor Endothelium but Not Tumor Cells to Inhibit Renal Cell Carcinoma Tumor Growth

MP21-17 SPHINGOSINE KINASE 1 OVEREXPRESSION CONTRIBUTES TO SUNITINIB RESISTANCE IN CLEAR CELL RENAL CELL CARCINOMA

Sunitinib significantly suppresses the proliferation, migration, apoptosis resistance, tumor angiogenesis and growth of triple-negative breast cancers but increases breast cancer stem cells

Suppression of Angiogenesis and Tumor Growth by Selective Inhibition of Angiopoietin-2

Inhibition of Tumor Growth and Sensitization to Sunitinib by RNA Interference Targeting Programmed Death-ligand 1 in Mouse Renal Cell Carcinoma RenCa Model

Abstract 23: Microrna302-367 Sphingosine 1 Phosphate Receptor 1 Pathway Prevents Tumor Growth Via Restricting Angiogenesis and Enhancing Vascular Stability

Anlotinib inhibits angiogenesis via suppressing the activation of VEGFR2, PDGFRβ and FGFR1.

Targeting Tumour Vasculature by Inhibiting Activin Receptor-Like Kinase (alk)1 Function

Anti-angiogenic Treatment Promotes Triple-Negative Breast Cancer Invasion Via Vasculogenic Mimicry